Onivyde for the therapy of multiple solid tumors

被引：119
作者：
Zhang, Haijun [1 ]
机构：
[1] Southeast Univ, Zhongda Hosp, Sch Med, Dept Oncol, 87 Dingjiaqiao, Nanjing 210009, Jiangsu, Peoples R China
来源：
ONCOTARGETS AND THERAPY | 2016年 / 9卷
基金：
中国国家自然科学基金;
关键词：
irinotecan; PEP02; MM-398; Onivyde; drug delivery system; tumor therapy; METASTATIC COLORECTAL-CANCER; MAGNETIC FE3O4 NANOPARTICLES; RANDOMIZED PHASE-II; PANCREATIC-CANCER; NANOLIPOSOMAL IRINOTECAN; 2ND-LINE CHEMOTHERAPY; GASTRIC-CANCER; GAMBOGIC ACID; PEP02; MM-398; GEMCITABINE;
D O I：
10.2147/OTT.S105587
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents, which has revolutionized tumor therapy. Onivyde, also known as MM-398 or PEP02, is a nanoliposomal formulation of irinotecan which has demonstrated encouraging anticancer activity across a broad range of malignancies, including pancreatic cancer, esophago-gastric cancer, and colorectal cancer. This up-to-date review not only focuses on the structure, pharmacokinetics, and pharmacogenetics of Onivyde but also summarizes clinical trials and recommends Onivyde for patients with advanced solid tumors.
引用
收藏
页码：3001 / 3007
页数：7
相关论文
共 34 条
  • [1] AKIMOTO K, 1994, CHEM PHARM BULL, V42, P2135, DOI 10.1248/cpb.42.2135
  • [2] Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
    Chang, T. C.
    Shiah, H. S.
    Yang, C. H.
    Yeh, K. H.
    Cheng, A. L.
    Shen, B. N.
    Wang, Y. W.
    Yeh, C. G.
    Chiang, N. J.
    Chang, J. Y.
    Chen, L. T.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 579 - 586
  • [3] PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer-A GERCOR Study.
    Chibaudel, Benoist
    Maindrault-Goebel, Frederique
    Andre, Thierry
    Bachet, Jean Baptiste
    Louvet, Christophe
    Khalil, Ahmed
    Dupuis, Olivier Jean Marie
    Hammel, Pascal
    Garcia, Marie Line
    Bennamoun, Mostefa
    Brusquant, David
    Arbaud, Claire
    Wang, Yi-Wen
    Yeh, Grace
    Bonnetain, Franck
    De Gramont, Aimery
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [4] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Conroy, Thierry
    Desseigne, Francoise
    Ychou, Marc
    Bouche, Olivier
    Guimbaud, Rosine
    Becouarn, Yves
    Adenis, Antoine
    Raoul, Jean-Luc
    Gourgou-Bourgade, Sophie
    de la Fouchardiere, Christelle
    Bennouna, Jaafar
    Bachet, Jean-Baptiste
    Khemissa-Akouz, Faiza
    Pere-Verge, Denis
    Delbaldo, Catherine
    Assenat, Eric
    Chauffert, Bruno
    Michel, Pierre
    Montoto-Grillot, Christine
    Ducreux, Michel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) : 1817 - 1825
  • [5] Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy
    Drummond, DC
    Noble, CO
    Guo, ZX
    Hong, K
    Park, JW
    Kirpotin, DB
    [J]. CANCER RESEARCH, 2006, 66 (06) : 3271 - 3277
  • [6] UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice
    Etienne-Grimaldi, Marie-Christine
    Boyer, Jean-Christophe
    Thomas, Fabienne
    Quaranta, Sylvie
    Picard, Nicolas
    Loriot, Marie-Anne
    Narjoz, Celine
    Poncet, Delphine
    Gagnieu, Marie-Claude
    Ged, Cecile
    Broly, Franck
    Le Morvan, Valerie
    Bouquie, Regis
    Gaub, Marie-Pierre
    Philibert, Laurent
    Ghiringhelli, Francois
    Le Guellec, Chantal
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 (03) : 219 - 237
  • [7] Garcia-Carbonero R, 2002, CLIN CANCER RES, V8, P641
  • [8] Hoff D. V., 2014, Annals of Oncology, V25, pii105, DOI [10.1093/annonc/mdu193.3, DOI 10.1093/ANNONC/MDU193.3]
  • [9] Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
    Kalra, Ashish V.
    Kim, Jaeyeon
    Klinz, Stephan G.
    Paz, Nancy
    Cain, Jason
    Drummond, Daryl C.
    Nielsen, Ulrik B.
    Fitzgerald, Jonathan B.
    [J]. CANCER RESEARCH, 2014, 74 (23) : 7003 - 7013
  • [10] Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
    Kang, Min H.
    Wang, Jing
    Makena, Monish R.
    Lee, Joo-Sang
    Paz, Nancy
    Hall, Connor P.
    Song, Michael M.
    Calderon, Ruben I.
    Cruz, Riza E.
    Hindle, Ashly
    Ko, Winford
    Fitzgerald, Jonathan B.
    Drummond, Daryl C.
    Triche, Timothy J.
    Reynolds, C. Patrick
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (05) : 1139 - 1150
1234